4//SEC Filing
Beldner Brett Douglas 4
Accession 0001193125-25-317190
CIK 0002078856other
Filed
Dec 11, 7:00 PM ET
Accepted
Dec 12, 11:51 AM ET
Size
5.3 KB
Accession
0001193125-25-317190
Insider Transaction Report
Form 4
Beldner Brett Douglas
Chief Financial Officer
Transactions
- Other
Common Stock
2025-12-04+31,840→ 31,840 total
Footnotes (1)
- [F1]On December 2, 2025, Hyperliquid Strategies Inc (the "Company") completed its previously announced business combination (the "Closing"), pursuant to the Business Combination Agreement, dated as of July 11, 2025 (as amended on September 22, 2025, the "BCA"), by and among the Company, Sonnet BioTherapeutics Holdings, Inc. ("Sonnet"), Rorschach I LLC, TBS Merger Sub Inc. and Rorschach Merger Sub, LLC . In connection with the Closing, Rorschach Capital LLC received an aggregate of 6,580,800 shares of common stock, par value $0.01 per share, of the Company (the "Common Stock"). On December 4, 2025, Rorschach Capital LLC distributed 31,840 shares of Common Stock to Mr. Beldner, a member of Rorschach Capital LLC.
Documents
Issuer
Hyperliquid Strategies Inc
CIK 0002078856
Entity typeother
Related Parties
1- filerCIK 0002098931
Filing Metadata
- Form type
- 4
- Filed
- Dec 11, 7:00 PM ET
- Accepted
- Dec 12, 11:51 AM ET
- Size
- 5.3 KB